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Background
In many tissues, a key mediator of cGMP signaling is
cGMP-dependent protein kinase I (PKG I). In vitro and in
vivo studies have shown that cGMP may not only regulate
the kinase activity but also the expression levels of PKG I.
Thus, chronic exposure of smooth muscle cells to high lev-
els of NO or NO donors, via increased cellular cGMP, sup-
presses PKG I expression, which may partly explain the
phenomenon of NO and/or nitrate tolerance. However, it
is not known whether the opposite situation, namely a
reduction in cellular cGMP levels, can increase PKG I
expression. To investigate this question, we examined the
expression and activity of PKG I in different tissues of
mice with genetic deletion of guanylyl cyclase-A (GC-A
KO), an in vivo model of reduced cGMP formation in
many different cell types.
Methods
The cyclic nucleotide (cGMP) contents of whole tissue
homogenates were determined with a specific radioim-
munoassay. Expression levels of PKG I, as well as phos-
phorylation of two specific target proteins, the
sarcoplasmic reticulum (SR) regulatory protein phos-
pholamban (PLB) as well as VASP (vasodilator-stimulated
phosphoprotein), were studied by Western blot analysis
and real-time RT-PCR (PKG I). Last, to evaluate possible
biological consequences, the role of PKG I in the modula-
tion of cardiomyocyte Ca2+ transients was studied in iso-
lated, electrically stimulated (0.5 Hz) ventricular
cardiomyocytes using the fluorescent dye indo-1AM.
Results
cGMP levels were reduced in the hearts, kidneys and aorta
of GC-A KO mice, while there were no differences in pul-
monary cGMP contents. Quantitative real-time RT-PCR
showed no differences in PKG I mRNA expression levels
between tissues from GC-A KO and wild-type (WT) mice.
In contrast, Western blot analyses revealed increased pro-
tein expression of PKG I in heart, lung, kidney and aorta
of GC-A KO mice. To determine endogenous kinase activ-
ity levels we measured PKG I-dependent phosphorylation
of cardiac PLB (at Ser16) and of renal and pulmonary
VASP (at the PKGI – specific site Ser239). PLB phosphor-
ylation was increased by 2-fold in GC-A KO hearts. VASP
phosphorylation was increased by 1.85-fold in lungs and
by 1.92-fold in renal papilas of GC-A KO as compared to
WT mice.
Last, because increased expression and activity of PKG I,
leading to enhanced PLB phosphorylation, may affect
SERCA2A activity and thereby SR calcium handling in GC-
A KO cardiomyocytes, we investigated the impact of the
observed changes on cardiomyocyte calcium handling.
GC-A KO cardiomyocytes showed increased systolic Ca2+i
levels (Indo 1 ratio 495 nm/405 nm: 1.64 ± 0.04 in GC-A
KO vs. 1.56 ± 0.04 in WT mice) whereas diastolic Ca2+i lev-
els were not different between genotypes (1.42 ± 0.01 vs.
1.42 ± 0.02). Selective inhibition of PKG I with the mem-
brane-permeant peptide inhibitor DT-2 (5 µM) had no
influence on systolic Ca2+ levels in wild-type cardiomyo-
cytes but caused a significant decrease in systolic Ca2+ lev-
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els in GC-A KO cardiomyocytes (1.6 ± 0.03 vs. 1.55 ±
0.04; P < 0.05).
Conclusion
Our results demonstrate that systemic deletion of the GC-
A receptor, causing a chronic depletion of cGMP within
many cell types, may cause an increase in PKG I expres-
sion. Notably, these changes in protein levels occurred in
the absence of changes in mRNA expression, suggesting
either increased synthesis or diminished degradation of
PKG I. The observation that cGMP levels in lungs were not
changed, while protein expression levels of PKG I were
increased deserves further investigation. Last, our study
reveals a previously unappreciated function of cardiac
PKG I in the regulation of PLB phosphorylation and
thereby in SR calcium handling.Page 2 of 2
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